International Orthopaedics

, Volume 35, Issue 10, pp 1569–1576 | Cite as

Regenerative medicine for the treatment of musculoskeletal overuse injuries in competition horses

  • Paola Torricelli
  • Milena Fini
  • Giuseppe Filardo
  • Matilde Tschon
  • Mario Pischedda
  • Alessandra Pacorini
  • Elizaveta KonEmail author
  • Roberto Giardino
Original Paper



Tissue repair in musculoskeletal injuries is often a slow and sometimes incomplete process. Regenerative medicine based on the use of growth factors (GFs) and cell therapy is aimed at improving the quality and speed of tendon and ligament healing. The aim of this study was to evaluate the potential for the administration of a combination of autologous platelet-rich plasma (PRP) and freshly isolated bone marrow mononucleated cells (BMMNCs) in 13 competition horses affected by overuse musculoskeletal injuries (suspensory ligament desmopathy and superficial flexor tendinopathy) and refractory to other therapies.


After ultrasonographic localisation of the lesion, the autologous BMMNC suspension and PRP were injected directly into the core lesion. BMMNC and platelet count as well as growth factors in PRP were measured to determine factors influencing the clinical outcome.


Horses showed a marked improvement in their degree of lameness and 84.6% were able to return to competition. Among all the factors studied, the platelet concentration predicted the healing time: significantly faster recovery (p = 0.049) was observed in cases of PRP with more than 750 × 103/μl platelets.


Competition horses are involved in highly demanding activities, thus being a similar model for the high mechanical overload typical of human athletes. The promising results obtained suggest that this combined biological approach may be useful even for the treatment of recalcitrant overuse musculoskeletal injuries in highly demanding patients if the appropriate dose of cells and GFs is applied.


Tendon Repair Autologous MSCs Human Athlete Undifferentiated Mesenchymal Stem Cell BMMNC Transplant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was partially supported by the project “Regione Emilia Romagna Programma di Ricerca Regione-Università 2007–2009” (Regenerative Medicine in Osteoarticular Disease).

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Lind M, Jakobsen BW, Lund B, Hansen MS, Abdallah O, Christiansen SE (2009) Anatomical reconstruction of the medial collateral ligament and posteromedial corner of the knee in patients with chronic medial collateral ligament instability. Am J Sports Med 37(6):1116–1122PubMedCrossRefGoogle Scholar
  2. 2.
    Kettunen JA, Kvist M, Alanen E et al (2002) Long term prognosis for jumper’s knee in male athletes. A prospective follow-up study. Am J Sport Med 30(5):689–692Google Scholar
  3. 3.
    Cook JL, Kiss ZS, Khan KM et al (2004) Anthropometry, physical performance, and ultrasound patellar tendon abnormality in elite junior basketball players: a cross sectional study. Br J Sports Med 38:206–209PubMedCrossRefGoogle Scholar
  4. 4.
    Koch TG, Berg LC, Betts DH (2009) Current and future regenerative medicine—principles, concepts, and therapeutic use of stem cell therapy and tissue engineering in equine medicine. Can Vet J 50:155–165PubMedGoogle Scholar
  5. 5.
    Anitua E, Andia I, Ardanza B et al (2004) Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 91:4–15PubMedGoogle Scholar
  6. 6.
    Borzini P, Mazzucco L (2007) Platelet-rich plasma (PRP) and platelet derivatives for topical therapy. What is true from the biologic view point? ISBT Sci Ser 2:272–281CrossRefGoogle Scholar
  7. 7.
    Huang Q, Wang YD, Wu T et al (2009) Preliminary separation of the growth factors in platelet-rich plasma: effects on the proliferation of human marrow-derived mesenchymal stem cells. Chin Med J (Engl) 122(1):83–87Google Scholar
  8. 8.
    Dallari D, Fini M, Stagni C et al (2006) In vivo study on the healing of bone defects treated with bone marrow stromal cells, platelet-rich plasma, and freeze-dried bone allografts, alone and in combination. J Orthop Res 24(5):877–888PubMedCrossRefGoogle Scholar
  9. 9.
    Chong AK, Chang J, Go JC (2009) Mesenchymal stem cells and tendon healing. Front Biosci 14:4598–4605PubMedCrossRefGoogle Scholar
  10. 10.
    Crovace A, Lacitignola L, Rossi G, Francioso E (2010) Histological and immunohistochemical evaluation of autologous cultured bone marrow mesenchymal stem cells and bone marrow mononucleated cells in collagenase-induced tendinitis of equine superficial digital flexor tendon. Vet Med Int 2010:250978PubMedGoogle Scholar
  11. 11.
    Smith RKW, Korda M, Blunn GW et al (2003) Isolation and implantation of autologous equine mesenchymal stem cells from bone marrow into the superficial digital flexor tendon as a potential novel treatment. Equine Vet 35:99–102CrossRefGoogle Scholar
  12. 12.
    Sánchez M, Anitua E, Azofra J, Andía I, Padilla S, Mujika I (2007) Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med 35(2):245–251PubMedCrossRefGoogle Scholar
  13. 13.
    Filardo G, Kon E, Della Villa S, Vincentelli F, Fornasari PM, Marcacci M (2010) Use of platelet-rich plasma for the treatment of refractory jumper’s knee. Int Orthop 34(6):909–915PubMedCrossRefGoogle Scholar
  14. 14.
    Kon E, Filardo G, Delcogliano M et al (2009) Platelet-rich plasma: new clinical application: a pilot study for treatment of jumper’s knee. Injury 40(6):598–603PubMedCrossRefGoogle Scholar
  15. 15.
    Del Bue M, Riccò S, Ramoni R et al (2008) Equine adipose-tissue derived mesenchymal stem cells and platelet concentrates: their association in vitro and in vivo. Vet Res Commun 32(S1):S51–S55PubMedCrossRefGoogle Scholar
  16. 16.
    Schnabel LV, Lynch ME, Van der Meulen MCH et al (2009) Mesenchymal stem cells and insulin-like growth factor-I gene-enhanced mesenchymal stem cells improve structural aspects of healing in equine flexor digitorum superficialis tendons. J Orthop Res 27(10):1392–1398PubMedCrossRefGoogle Scholar
  17. 17.
    McCarrel T, Fortier L (2009) Temporal growth factor release from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression. J Orthop Res 27(8):1033–1042PubMedCrossRefGoogle Scholar
  18. 18.
    Dowling BA, Dart AJ, Hodgson DR et al (2000) Superficial digital flexor tendonitis in the horse. Equine Vet J 25:913–925Google Scholar
  19. 19.
    Fortier LA, Smith RKW (2008) Regenerative medicine for tendinous and ligamentous injuries of sport horses. Vet Clin Equine 24:191–201CrossRefGoogle Scholar
  20. 20.
    Guest DJ, Smith MR, Allen WR (2008) Monitoring the fate of autologous and allogenic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses. Preliminary study. Equine Vet J 40:178–181PubMedCrossRefGoogle Scholar
  21. 21.
    Arthur A, Zannettino A, Gronthos S et al (2009) The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. J Cell Physiol 218:237–245PubMedCrossRefGoogle Scholar
  22. 22.
    Lacitignola L, Crovace A, Rossi G, Francioso E (2008) Cell therapy for tendinitis, experimental and clinical report. Vet Res Commun 32(Suppl 1):S33–S38PubMedCrossRefGoogle Scholar
  23. 23.
    Giannini S, Buda R, Vannini F et al (2009) One-step bone marrow-derived cell transplantation in talar osteochondral lesions. Clin Orthop Relat Res 467(12):3307–3320PubMedCrossRefGoogle Scholar
  24. 24.
    Anitua E, Sanchez M, Nurden AT et al (2006) New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 24:227–234PubMedCrossRefGoogle Scholar
  25. 25.
    Marx RE (2000) Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation. J Oral Maxillofac Surg 58:300–301CrossRefGoogle Scholar
  26. 26.
    Borzini P, Mazzucco L (2005) Tissue regeneration and in-loco administration of platelet derivatives. Clinical outcome, heterogeneous products, eterogeneity of the effector mechanisms. Transfusion 35:1759–1767CrossRefGoogle Scholar
  27. 27.
    Weibrich G, Kleis WKG, Hitzler WE, Hafner G (2005) Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasma: a technical report. Int J Oral Maxillofac Implants 20:118–123PubMedGoogle Scholar
  28. 28.
    Lindemann S, Tolley ND, Dixon DA et al (2001) Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J Cell Biol 154(3):485–490PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Paola Torricelli
    • 1
  • Milena Fini
    • 1
  • Giuseppe Filardo
    • 2
  • Matilde Tschon
    • 1
  • Mario Pischedda
    • 3
  • Alessandra Pacorini
    • 3
  • Elizaveta Kon
    • 2
    Email author
  • Roberto Giardino
    • 1
  1. 1.Laboratory of Preclinical and Surgical Studies, Research Institute Codivilla-PuttiRizzoli Orthopaedic InstituteBolognaItaly
  2. 2.Laboratory of Biomechanics and Technology Innovation– III ClinicRizzoli Orthopaedic InstituteBolognaItaly
  3. 3.Veterinary StudioBolognaItaly

Personalised recommendations